All In Biotech

Drug Trial Radar · NCT03257098

Allogeneic ABCB5-positive Stem Cells for Treatment of CVU

An Interventional, Single Arm, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Chronic Venous Ulcer (CVU)

Last checked: Nov 20, 2026Latest source record: Sep 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31

Actual

Start

Nov 16, 2017

Primary completion

Jun 25, 2020

Study completion Jun 25, 2020

Sponsor

Lead sponsor
RHEACELL GmbH & Co. KGIndustry
Sponsor type
Industry
Collaborators
FGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & Services
First posted
Aug 22, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 35 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction of Chronic Venous Ulcers) and safety (by monitoring adverse events) of the medicinal product to be studied after two applications on the wound surface in patients with Chronic Venous Ulcers.

Conditions

  • Skin Ulcer Venous Stasis Chronic

Interventions

  • allo-APZ2-CVUBiological

    Suspension of ABCB5-positive mesenchymal stem cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of wound size reductionTime frame: Week 12 post baseline, or last available post-baseline measurement if the Week 12 measurement is missing
  2. Assessment of adverse event (AE) occurrenceTime frame: Up to 12 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken, Kliniken der Ruhr-Universität Bochum im St. Maria Hilf Krankenhaus

    Bochum, Germany

  • Universitätsklinikum Erlangen, Hautklinik

    Erlangen, Germany

  • Klinik und Poliklinik für Hautkrankheiten, Universitätsmedizin Greifswald

    Greifswald, Germany

  • Klinische Forschung Hamburg GmbH, Dermatologie / Allergologie

    Hamburg, Germany

  • pro scientia med im Mare Klinikum; Department Klinische Forschung und Entwicklung

    Kiel, Germany

  • Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie

    Münster, Germany

  • Klinische Forschung Schwerin GmbH

    Schwerin, Germany

  • Universitätsklinikum Ulm, Klinik für Dermatologie und Allergologie

    Ulm, Germany

  • Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg

    Würzburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.